TICKERNERD
Menu
YCBDYCBDHealthcare · Drug Manufacturers - Specialty & Generic

YCBD Stock Forecast: cbdMD, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$0.57
+12.33% on the day

The 1 Wall Street analysts covering cbdMD, Inc. hold a median 12-month price target of $2 — +251.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$6.0M
Ticker Nerd rank
49 / 100
Median analyst target
$2.00
Analysts covering
1
Total return, dividends reinvested
1W
+9.5%
1M
−16.9%
YTD
−57.8%
1Y
−33.8%
From 52W high
−74.9%
From 52W low
+21.2%
$0.47
$2.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

YCBD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores cbdMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Revisions
70
Quality
68
Issuance
47
Growth
44
Momentum
38
Accruals
28
Value
27
Volatility
23

Size (96): Smaller than most of the companies we track.

Volatility (23): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own cbdMD, Inc. — and when they’d sell — is the membership.

Wall Street

YCBD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on YCBD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Oct 25Jan 26Apr 26Jul 26YCBDHigh $2.00Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $2.00Median $2.00High $2.00

The green dot is the last close — the median target sits +251.2% from it.

Recent analyst actionsNewest first

Of the 10 most recent actions, 4 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
20 Aug 2025Maxim GroupMaintainsBuy—
22 May 2025Maxim GroupMaintainsBuy—
5 Oct 2023Maxim GroupInitiatesBuy—
18 June 2021Cantor FitzgeraldReinstatesNeutral$4.10 → $3.25
3 Feb 2021Cantor FitzgeraldReiteratesNeutral$4.30 → $4.10
29 Jan 2021Cantor FitzgeraldMaintainsNeutral$3.60 → $4.30
9 Sept 2020BenchmarkMaintainsSpeculative Buy$3.00 → $4.00
13 Aug 2020Cantor FitzgeraldMaintainsNeutral$1.80 → $3.60
18 May 2020Cantor FitzgeraldMaintainsNeutral$1.20 → $1.80
19 Dec 2019BenchmarkMaintainsSpeculative Buy$9.00 → $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

YCBD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

cbdMD, Inc. (YCBD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
0.3×

Cheaper than 89% of US stocks

Price / book
0.6×

Cheaper than 81% of US stocks

EV / EBITDA
−1.9×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
18.8%

Higher than 70% of US stocks

Earnings growth (YoY)
18.8%

Higher than 60% of US stocks

Gross margin
57.7%

Higher than 72% of US stocks

Operating margin
−14.2%

Higher than 24% of US stocks

Net margin
−13.3%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−53.4%

Higher than 20% of US stocks

Return on assets
−14.4%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

YCBD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
YCBDcbdMD, Inc.$6.0M
49
SNOASonoma Pharmaceuticals, Inc.$5.3M
24
INMInMed Pharmaceuticals, Inc.$4.9M
22
GELSGelteq Ltd.$5.6M
11
APUSApimeds Pharmaceuticals US, Inc.$7.8M
8
PRFXPRF Technologies Ltd.$3.0M
3
SBFMSunshine Biopharma, Inc.$2.8M
43
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. YCBD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest YCBD news & analysis

cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products

PRNewsWire · 3 Aug 2026positive

cbdMD has publicly welcomed a proposed U.S. Senate spending bill that, if enacted, would delay federal restrictions on full-spectrum CBD and other naturally derived hemp products slated to take effect in November.

Why it matters — A delay in federal hemp restrictions could allow cbdMD to continue selling its full-spectrum products without disruption, directly affecting the company's core business.

cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access

PRNewsWire · 24 July 2026positive

cbdMD announced its support for the bipartisan Lawful Hemp Protection Act, introduced July 21 by Rep. Barr and Sen. Craig, aiming to fix the federal hemp definition and protect full-spectrum CBD access for consumers.

Why it matters — A YCBD watcher would care because the proposed legislation directly affects cbdMD's ability to produce and sell full-spectrum hemp-derived wellness products under federal law.

FAQ

Frequently asked questions about YCBD stock

What is the YCBD stock price forecast for 2026-2027?

The 1 Wall Street analysts covering cbdMD, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is YCBD stock a buy right now?

Of the 1 analysts covering cbdMD, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks cbdMD, Inc. 49 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank YCBD?

As at 1 Aug 2026, cbdMD, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will YCBD stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +251.2% from the last close, and Ticker Nerd's factor model ranks cbdMD, Inc. 49 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the YCBD stock forecast for 2030?

No analyst covering cbdMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YCBD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has YCBD stock performed over the past year?

cbdMD, Inc. returned -33.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does cbdMD, Inc. do?

cbdMD, Inc. is a prominent player in the cannabidiol (CBD) industry, focusing on the production and distribution of high-quality, hemp-derived CBD products.

What is the latest news on YCBD?

The most recent item we track (PRNewsWire, 3 Aug 2026): "cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products". cbdMD has publicly welcomed a proposed U.S. Senate spending bill that, if enacted, would delay federal restrictions on full-spectrum CBD and other naturally derived hemp products slated to take effect in November.

Company

About cbdMD, Inc.

cbdMD, Inc. is a prominent player in the cannabidiol (CBD) industry, focusing on the production and distribution of high-quality, hemp-derived CBD products. The company's main purpose is to develop a diverse range of wellness products, which include tinctures, gummies, topicals, and bath bombs, designed to enhance personal health and wellness. cbdMD stands out in the competitive CBD market by prioritizing quality and purity, utilizing industry-leading manufacturing processes and rigorous third-party testing to ensure its products are THC-free and meet stringent standards. With its headquarters in Charlotte, North Carolina, cbdMD has positioned itself as a key contributor to the rapidly growing cannabis and wellness sectors. It serves both retail and wholesale clients across various channels, including e-commerce platforms, specialty health stores, and professional sports organizations. By leveraging strategic marketing and product innovation, cbdMD, Inc. continues to play a critical role in educating consumers and expanding the acceptance of CBD as a viable health supplement.

CEO Mr. T. Ronan Kennedy · 42 employees · United States · https://www.cbdmd.com